WHO makes new executive board appointments

The World Health Organization (WHO) has made one new and one renewed appointment to its executive board: Zsuzsanna Jakab has been named WHO regional director for Europe, while Dr Luis Gomes Sambo has been re-appointed WHO regional director for Africa. Mrs Jakab, who was previously director of the European Centre for Disease Prevention and Control, succeeds Dr Marc Danzon, who has served as European regional director for the past 10 years. Dr Sambo first took the role as regional director for Africa in 2005; before that he held a number of health-based roles in Angola, including vice-minister of health, director of health service in the Cabinda province and director of international co-operation at the ministry of health in Luanda.

The World Health Organization (WHO) has made one new and one renewed appointment to its executive board: Zsuzsanna Jakab has been named WHO regional director for Europe, while Dr Luis Gomes Sambo has been re-appointed WHO regional director for Africa. Mrs Jakab, who was previously director of the European Centre for Disease Prevention and Control, succeeds Dr Marc Danzon, who has served as European regional director for the past 10 years. Dr Sambo first took the role as regional director for Africa in 2005; before that he held a number of health-based roles in Angola, including vice-minister of health, director of health service in the Cabinda province and director of international co-operation at the ministry of health in Luanda.

Welcome to Scrip

Create an account to read this article

More from Business

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By 

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?